Evaluating the Effects of Prebiotics on Sleep, the Gut Microbiome, Cognition, Immune Function and Stress
Study Details
Study Description
Brief Summary
The aim of the proposed randomised, double-blind, controlled, parallel groups trial is to assess the sleep, gut microbiome, cognitive, immune and stress effects of 56 days administration of three formulations of a prebiotic-based intervention, in comparison to a placebo control, in a cohort of healthy adults reporting poor sleep quality.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Investigational Supplement 1 (INV-1) The total daily supplement to be consumed by participants is 33.0 g. This will be administered as 2 separate doses mixed with water, a 16.5 g dose (two 8.25 g sachets) to be consumed in the morning (AM dose) and a 16.5 g dose (two 8.25 g sachets) to be consumed in the evening (PM dose). Supplementation will last 56 days. |
Dietary Supplement: Prebiotic
The bioactive ingredients used in this study include bovine milk fat globule membrane (MFGM), bovine lactoferrin and a prebiotic blend of polydextrose and galactooligosaccharides (PDX/GOS).
|
| Active Comparator: Investigational Supplement 1 (INV-2) The total daily supplement to be consumed by participants is 33.0 g. This will be administered as 2 separate doses mixed with water, a 16.5 g dose (two 8.25 g sachets) to be consumed in the morning (AM dose) and a 16.5 g dose (two 8.25 g sachets) to be consumed in the evening (PM dose). Supplementation will last 56 days. |
Dietary Supplement: Prebiotic
The bioactive ingredients used in this study include bovine milk fat globule membrane (MFGM), bovine lactoferrin and a prebiotic blend of polydextrose and galactooligosaccharides (PDX/GOS).
|
| Active Comparator: Investigational Supplement 1 (INV-3) The total daily supplement to be consumed by participants is 33.0 g. This will be administered as 2 separate doses mixed with water, a 16.5 g dose (two 8.25 g sachets) to be consumed in the morning (AM dose) and a 16.5 g dose (two 8.25 g sachets) to be consumed in the evening (PM dose). Supplementation will last 56 days. |
Dietary Supplement: Prebiotic
The bioactive ingredients used in this study include bovine milk fat globule membrane (MFGM), bovine lactoferrin and a prebiotic blend of polydextrose and galactooligosaccharides (PDX/GOS).
|
| Placebo Comparator: Control The total daily supplement to be consumed by participants is 33.0 g. This will be administered as 2 separate doses mixed with water, a 16.5 g dose (two 8.25 g sachets) to be consumed in the morning (AM dose) and a 16.5 g dose (two 8.25 g sachets) to be consumed in the evening (PM dose). Supplementation will last 56 days. |
Other: Control
Maltodextrin
|
Outcome Measures
Primary Outcome Measures
- Lab-recorded polysomnography- Sleep Quality [Change from protocol days 2 and 3 (baseline) and 59 and 60 following 56 days of supplement consumption]
percentage of time in staged sleep from total sleep recorded time
Secondary Outcome Measures
- Lab-recorded polysomnography- Sleep onset latency [Change from protocol days 2 and 3 (baseline) and 59 and 60 following 56 days of supplement consumption]
minutes taken from intention to sleep to first epoch of any stage of sleep
- Lab-recorded polysomnography- Total sleep time [Change from protocol days 2 and 3 (baseline) and 59 and 60 following 56 days of supplement consumption]
minutes of staged sleep over entire sleep duration period
- Lab-recorded polysomnography- Number of awakenings [Change from protocol days 2 and 3 (baseline) and 59 and 60 following 56 days of supplement consumption]
number of <15 second bouts of Wake surrounded, at both ends, by any sleep stage
- Lab-recorded polysomnography- Wake after sleep onset [Change from protocol days 2 and 3 (baseline) and 59 and 60 following 56 days of supplement consumption]
cumulative minutes of scored Wake during entire sleep duration following sleep initiation
- Lab-recorded polysomnography- Time spent in stages of rapid eye movement (REM) and non-REM sleep [Change from protocol days 2 and 3 (baseline) and 59 and 60 following 56 days of supplement consumption]
percentage of time spent in REM, N1, N2, N3
- Lab-recorded polysomnography- REM Rebound [Change from protocol days 2 and 3 (baseline) and 59 and 60 following 56 days of supplement consumption]
length, frequency and depth of REM sleep
- Lab-recorded polysomnography- Sleep microstructure [Change from protocol days 2 and 3 (baseline) and 59 and 60 following 56 days of supplement consumption]
including k-complexes - >.0.5 secs. negative then positive wave and fast/slow sleep spindles - >.0.5 secs. sinusoidal waves 11-16Hz
- Actigraphy - Sleep onset latency [Change from baseline following 56 days of supplement consumption]
recorded minutes taken from intention to sleep to sleep initiation
- Actigraphy - Total sleep time [Change from baseline following 56 days of supplement consumption]
recorded minutes asleep over entire sleep period
- Actigraphy - Number of awakenings [Change from baseline following 56 days of supplement consumption]
recorded number of awakenings during entire sleep period
- Actigraphy - Wake after sleep onset (WASO) [Change from baseline following 56 days of supplement consumption]
recorded minutes awake during the entire sleep period following sleep onset
- Actigraphy - Sleep efficiency [Change from baseline following 56 days of supplement consumption]
ratio of the total time spent asleep (total sleep time) in a night compared to the total amount of time spent in bed (percentage)
- Blood Pressure and Heart Rate (BP/HR) [Change from baseline following 56 days of supplement consumption]
Measured using a fully automatic oscillometric device
- Body Mass Index (BMI) [Change from baseline following 56 days of supplement consumption]
calculated using standard formula: weight (kg) / [height (m)]2
- Waist-to-Hip Ratio (WHR) [Change from baseline following 56 days of supplement consumption]
WHR will be calculated by dividing waist circumference by hip circumference.
- Pittsburgh Sleep Quality Index (PSQI) [Change from baseline following 56 days of supplement consumption]
Pittsburgh Sleep Quality Index (PSQI): Total Score. The PSQI is a validated self-rating instrument assessing aspects of sleep quality.Minimum score 0 (better); maximum score 21 (worse) < or = 5 associated with good sleep quality; > 5 associated with poor sleep quality.
- Profile of Mood States (POMS) [Change from baseline following 56 days of supplement consumption]
Profile of Mood States (POMS): Mood scores. The Profile of Mood States (POMS) is a psychological rating scale used to assess transient, distinct mood states. 65 adjectives rated on 5-point scale 0= not at all; 1=a little; 2=moderately; 3=quite a bit; 4=extremely. Factor analysis: 6 subscales tension-anxiety (9 items, score range: 0-36) depression (15 items, range 0-60) anger-hostility (12 items, range 0-48) vigor-activity (8 items, range 0-32) fatigue (7 items, range 0-28) confusion-bewilderment (7 items, range 0-28) Total mood disturbance (TMD): (range 0-200)
- Depression, Anxiety and Stress Scale - 21 Items (DASS-21) [Change from baseline following 56 days of supplement consumption]
A 21-item measure of mood over the previous week (each item is rated on scale from 0-3). Scoring creates 3 component scores: depression, anxiety and stress (each on a scale of 0-21) with higher scores indicating higher symptomology. Cut-off scores, according to each set of symptoms, are available (normal, mild, moderate, severe and extremely severe) or total scores can be derived by multiplying the sum of all three component scores by 2.
- State-Trait Anxiety Inventory (STAI) [Change from baseline following 56 days of supplement consumption]
A 40-item measure of current and general anxiety levels. Each item is rated on a scale from 1-4. Scoring creates two components: state anxiety (20 items) and trait anxiety (20 items), with a range for each between 20-80. Following transformation through reversed coding, higher scores indicate higher levels of anxiety.
- Work Productivity and Activity Impairment questionnaire (WPAI) [Change from baseline following 56 days of supplement consumption]
A 6-item measure of the impact of an individual's health on their work over the previous week. There are 4 component scores: presenteeism, activity impairment, absenteeism and overall work productivity. All items have varying response formats and higher scores indicate more impairment in each domain. Overall scores can also be summed and multiplied by 100 for an overall impairment index.
- 12-Item Short Form Survey (SF-12) [Change from baseline following 56 days of supplement consumption]
A 12-item measure of current perceptions of health status. All items have varying response formats and result in 8 component scores: 1) Limitations in physical activities because of health problems, 2) Limitations in social activities because of physical or emotional problems, 3) Limitations in usual role activities because of physical health problems, 4) Bodily pain, 5) General mental health (psychological distress and well-being), 6) Limitations in usual role activities because of emotional problems, 7) Vitality (energy and fatigue) and 8) General health perceptions.
- Perceived Stress Scale (PSS [Change from baseline following 56 days of supplement consumption]
Perceived Stress Scale (PSS): Total Score. The PSS is comprised of 14 items intended to measure how unpredictable, uncontrollable, and overloaded individuals find their life circumstances.Participants rate items on a 5-point Likert scale, ranging from 0 - "Never" to 4 - "Very often." Scores range from 0-56 higher scores indicate greater perceived stress
- Gastrointestinal symptoms questionnaire [Change from baseline following 56 days of supplement consumption]
This in-house developed questionnaire is to be completed at the start and end of the trial, during the baseline and chronic lab visits respectively. When completing the assessment, participants will answer in relation to their experiences in the previous 7 days. The questionnaire asks 11 questions, plus a 12th open-ended question, about gastrointestinal experiences, with 5 possible ratings; 'not at all' (score of 0), 'A little' (score of 1), 'a moderate amount' (score of 2), 'quite a lot' (score of 3) and 'a severe amount' (score of 4). Scores can range between 0-44 with a higher score indicating a more negative experience of symptoms
- Sleep Diary -Total Sleep Time [Change from baseline following 56 days of supplement consumption]
how long, in minutes, the individual reports being asleep during the night between initiation and termination of sleep, accounting for nocturnal wake periods
- Sleep Diary -Time in bed [Change from baseline following 56 days of supplement consumption]
how long, in minutes, the individual reports being in bed intending to sleep
- Sleep Diary -Sleep Latency [Change from baseline following 56 days of supplement consumption]
how long, in minutes, the individual felt it took them to fall asleep after intending to sleep
- Sleep Diary -Number of Awakenings [Change from baseline following 56 days of supplement consumption]
number of perceived awakenings over the sleep period
- Sleep Diary - Wake After Sleep Onset (WASO) [Change from baseline following 56 days of supplement consumption]
how long, in minutes, the individual reports being awake during the night after sleep initiation
- Sleep Diary - Sleep Efficiency [Change from baseline following 56 days of supplement consumption]
Total Sleep Time divided by Time in Bed x 100, expressed as a percentage
- Sleep Diary - Sleep Quality [Change from baseline following 56 days of supplement consumption]
4 items (each scored on a 0-4 scale) covering nocturnal physical and psychological tension, sleep enjoyment and feelings of restedness. Items can be summed (range 0-16) with higher scores indicating poorer sleep quality.
- Dietary assessment- Intake24 [Change from baseline following 56 days of supplement consumption]
The Intake 24 measure (https://intake24.co.uk/) will assess participants dietary recall over the previous 24 hour period. The generated results provide an indication of overall calorie intake as well as fibre, sugar, calcium, total fat, saturated fat, vitamin C, iron, folate, fruit and vegetable and red meat intake.
- Perceived sleep quality (VAS) [Change from baseline following 56 days of supplement consumption]
Assessed weekly via numerical rating scales. This will generate individual scores of 0-4 (0= 'Extremely poor' to 4= 'Extremely good')
- Subjective Stress (VAS) [Change from baseline following 56 days of supplement consumption]
Assessed weekly via numerical rating scales. This will generate individual scores of 0-4 (0= 'Extremely poor' to 4= 'Extremely good')
- Subjective mood (VAS) [Change from baseline following 56 days of supplement consumption]
Assessed weekly via numerical rating scales. This will generate individual scores of 0-4 (0= 'Extremely poor' to 4= 'Extremely good')
- Subjective productivity (VAS) [Change from baseline following 56 days of supplement consumption]
Assessed weekly via numerical rating scales. This will generate individual scores of 0-4 (0= 'Extremely poor' to 4= 'Extremely good')
- COMPASS global performance measures [Change from baseline following 56 days of supplement consumption]
Speed of performance, and accuracy of performance measured by Computerised Mental Performance Assessment System (COMPASS, Northumbria University)
- Cognitive domain factor score [Change from baseline following 56 days of supplement consumption]
Speed of attention, accuracy of attention, speed of memory, accuracy of working memory, and accuracy of episodic memory measured by Computerised Mental Performance Assessment System (COMPASS, Northumbria University)
- Cognitive Function under stressful conditions [Change from baseline following 56 days of supplement consumption]
Cognitive performance (multi tasking using Serial Subtractions (3s, 7s, 17s) and tracking simultaneously) during acute stress as a consequence of theOBSERVED MULTITASKING STRESSOR (OMS)
- Changes in subjective stress; as assessed by the 'state, trait anxiety inventory' (STAI) [Change from baseline following 56 days of supplement consumption]
Subjective stress will be measured via the state, trait anxiety inventory before and after each completion of the observed multitasking stressor (OMS)
- Changes in objective stress; as assessed by salivary cortisol levels [Change from baseline following 56 days of supplement consumption]
Saliva samples will be taken from participants before and after each completion of the observed multitasking stressor (OMS) and the change in salivary cortisol levels between pre- and post-OMS
- Changes in objective stress; as assessed by salivary alpha-amylase levels [Change from baseline following 56 days of supplement consumption]
Saliva samples will be taken from participants before and after each completion of the observed multitasking stressor (OMS) and the change in salivary cortisol levels between pre- and post-OMS
- Changes in objective stress; as assessed by galvanic skin response (GSR) [Change from baseline following 56 days of supplement consumption]
Galvanic skin response (GSR) will be recorded throughout the observed multitasking stressor (OMS)
- Changes in objective stress; as assessed by heart rate (HR) [Change from baseline following 56 days of supplement consumption]
Heart rate (HR) will be recorded throughout the observed multitasking stressor (OMS)
- Gut microbiome assessments (gut bacterial profile) [Change from baseline following 56 days of supplement consumption]
Assessed via analysis of self collected stool samples at baseline, during active supplementation and after 56 days of supplementation.
- Immunological marker Assessment -Blood [Change from baseline following 56 days of supplement consumption]
Immune function (identification of blood biomarkers of immune function in samples collected at baseline and chronic lab visits)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Participants must self-assess themselves as being in good health.
-
Have a stable sleep/wake schedule (bedtime between 9pm and 1am and wake time between 6am and 10am at least 5 nights per week)
-
Aged 25 to 60 years at the time of randomisation
-
Fluent in English
-
Identify as a 'poor sleeper' as defined subjectively (i.e. poor sleep quality, unrefreshing sleep) and a total score of >5 on the Pittsburgh Sleep Quality Index (PSQI).
Exclusion Criteria:
-
Member of own household currently participating in this trial
-
Evidence of current or recent sleep disorders (e.g. sleep apnoea, insomnia, circadian rhythm disorders), taking any medication which exerts sedative effects, affects the CNS and/or sleep, or be currently unwell with any illness that affects sleep (i.e. disorders of the CNS). An initial screening for sleep disorders will be conducted using the Sleep Disorders Symptom Checklist-25 (SDS-CL; Klingman et al., 2017). If a participant reports positively to any of the 25 questions in terms of being affected for three nights per week, or more, this will be followed up using a clinical interview according to the International Classification of Sleep Disorders (ICSD-3) to exclude on the basis of a sleep disorder
-
History of seizures or epilepsy
-
Shift working or have a history of shift work within the previous six months
-
Currently, or within the previous 8 weeks, consuming any prebiotic or probiotic products/supplements (including specifically oligosaccharides)
-
Participation in any other intervention research trials
-
Sleeping at a location other than their usual residence more than two nights per week during participation
-
Travel across multiple time zones within the last three months or have planned travel across multiple time zones during the study
-
Current or recent mood disturbances or Axis I disorders
-
Current misuse of alcohol and/or drugs
-
Current smoker
-
Recent (within the last 12 weeks) infection and/or use of antibiotic medication
-
Pregnant, seeking to become pregnant or lactating
-
Those using (including within the last 2 weeks) proton-pump inhibitors
-
Milk allergy
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Northumbria Sleep Research, Northumbria University | Newcastle | United Kingdom |
Sponsors and Collaborators
- Northumbria University
- Reckitt Benckiser Group PLC
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 35654